What`s new in endometrial cancer research and treatment?
Molecular pathology of endometrial cancer
Recent research has improved our understanding of how changes in certain molecules can cause normal endometrial cells to become cancerous. For several years we have known that damaged or defective DNA (called mutations) can alter important genes that regulate cell growth. If these genes are damaged, out-of-control growth may result in cancer.
Sometimes, endometrial cancer and colon cancer may seem to “run in a family.” We now know that some of these families have a higher risk for these cancers because they have an inherited defect in certain genes that normally help repair damage to DNA. If these repair enzymes are not working properly, damage to DNA is more likely to persist and cause cancer. Similar DNA repair defects have also been found in endometrial cancer cells from some patients without an inherited tendency to develop this disease. One of the normal genes responsible for suppressing tumor growth, called PTEN, is often abnormal in endometrial cancers.
Tests for this and other DNA changes may someday help find endometrial cancers early. Endometrial cancers without other tumor suppressor genes (or with inactive ones), such as the retinoblastoma (Rb) gene and the TP53 gene, tend to be more likely to come back after initial treatment. Tests for these and other DNA changes may someday be used to help predict how aggressive the cancer might be and to select the best treatment for each woman with this disease. The long-range goal of this field of research is gene therapy that can correct the DNA abnormalities that caused the endometrial cells to become cancerous.
Researchers are examining new drugs, combinations of drugs and “targeted therapies” in patients with advanced endometrial cancer. The use of adjuvant chemotherapy, with or without radiation is also under investigation.
As researchers have learned more about the gene and protein changes in cancer cells, they have been able to develop newer drugs that specifically target these changes. These targeted drugs work differently from standard chemotherapy (chemo) drugs. They often have different side effects. Some targeted therapy that are being studied to treat endometrial cancer include temsirolimus, brivanib, and gefitinib.
Although hormone therapy of endometrial cancer has often involved progestins, drugs that affect estrogen may also be helpful. A recent study looked at using fulvestrant (Faslodex®), a drug that blocks estrogen receptors.
Another way to see if cancer has spread to the lymph nodes in the pelvis is to identify and remove the lymph nodes that most likely are draining the cancer. This is called sentinel lymph node biopsy. In this procedure, radioactive tracer and/or blue dye is injected into the area with the cancer. The lymph nodes that turn blue (from the dye) or that become radioactive (from the tracer) are removed at surgery. These lymph nodes are examined closely to see if they contain any cancer cells. This technique is commonly used for some other tumors, such as breast cancer, but it is still new in the treatment of endometrial cancer. It is not yet known if sentinel lymph node biopsy is as good as lymph node dissection for staging and treating endometrial cancer, so it is not currently part of the standard surgery for this cancer.
Last Medical Review: 01/12/2015
Last Revised: 03/17/2015